Contact Us
LAM Australasia Research Alliance
Janet +61 411 816 444
PO Box 636 Bondi Junction NSW 1355
Australia
The LAM Australasia Research Alliance (LARA) is dedicated to improving the health prospects of women with LAM in Australia, New Zealand and throughout the region. A disease that affects only women, LAM is rare and often devastating.
ALL DONATIONS TO LARA ARE FULLY TAX DEDUCTIBLE
Your contribution to LARA will go 100% to funding vital medical research to find a cure for LAM.
You can donate to the LAM Australasia Research Alliance by sending us a cheque, using our PayPal facility, or by making a deposit directly to our ANZ Bank account: 012 055 4926 67193.
Please advise us of your donation by sending an email to admin@lara.org.au with your name, address and email address. We will respond with our thanks and a fully tax deductible receipt.
Major Donors
Macquarie Group Foundation
Roth Charitable Foundation
Mr Robert Gavshon
Hollick Wines
Acknowledgements
LARA thanks the professionals who work pro bono for this not-for-profit organisation. We highly recommend the services of:
Ben Higham, Webhead
Karen Riethmuller, KGR Design
Peter Hersh, Loggica Pty Ltd
Peter Kelso
Research
|
Registered Nurse Denise Haylen is interviewing women living with LAM in various parts of Australia.
|
|
Download the PDF
|
|
LAM Foundation Scientist Dr. Elizabeth Henske responds to LAM patients' questions about LAM and Cancer Source: The LAM Foundation (USA) Dr. Elizabeth (Lisa) Henske is a Tenured Senior Member of Fox Chase Cancer Center in Philadelphia. She earned her undergraduate degree summa cum laude from Yale University, where she maj...
|
|
Early in 2011, the Cell Biology group of the Woolcock Institute of Medical Research received what is thought to be the first ever Australian National Health and Medical Research Council grant for studies investigating Lymphangioleiomyomatosis (LAM). The grant runs for three years from 2011.
|
|
Research known as the MILES Trial reveals that while being treated with the drug, sirolimus (rapamycin), for one year, patients showed a small but significant improvement in lung function*.
|
|
Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for patients with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), who require therapeutic intervention but are not candidates fo...
|
|
Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.
|
|
Although misdiagnosis or missed diagnosis still exists, doctors in mainland China are becoming increasingly vigilant about PLAM.
|
|
Researchers at the University of Cincinnati and Cincinnati Children's Hospital Medical Center have established that a particular blood test can successfully identify lymphangioleiomyomatosis (LAM).
|
|
This project aims to determine whether LAM cells are capable of growing under conditions that favour the generation of self-renewing cancer stem cell-like cells.
|
|
Author: Joel Moss MD PhD Deputy Chief, Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health. Coauthor: John A Kelly MB BCh MD Assistant Professor of Medicine and Micro-Immunology, Dartmouth Medical School
|
|
Terasaki Y, Yahiro K, Pacheco-Rodriguez G, Steagall WK, Stylianou MP, Evans JF, Walker AM, Moss J. Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States.
|
|
Researchers at the Malaghan Institute for Medical Research in Wellington New Zealand have embarked on a one year pilot program studying LAM cells...
|
|
Dr Deborah Yates, Department of Thoracic Medicine, St Vincent's Hospital, Sydney. In 2008 we started enrolling women with LAM for the Doxycycline in LAM trial...
|
|
During a six month visit by Dr Lyn M Moir to Dr Vera Krymskaya’s laboratory, University of Pennsylvania, Philadelphia, PA, USA...
|